Skip to content

Safety evaluation for excessive intake of drink containing plant derived extractive.

Safety evaluation for excessive intake of drink containing plant derived extractive. - Safety evaluation for excessive intake of drink containing plant derived extractive.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000028223
Enrollment
10
Registered
2017-07-13
Start date
2017-07-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects

Interventions

Intake of drink containing plant derived extractive, 3-fold quantity of recommended daily intake, for 4 consecutive weeks.

Sponsors

TTC Co.,Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Healthy males and females aged 20-64 years old.

Exclusion criteria

Exclusion criteria: 1. Subjects who constantly use supplements in addition to the normal meal richly containing polyphenol. 2. Subjects having a current or past history of serious diseases such as diabetes, hepatic or renal disorder, or cardiovascular disease. 3. Subjects having possibilities for emerging allergy related to the study. 4. Subjects having a disease requiring treatment or a history of serious diseases for which medication was required. 5. Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination on preliminary examination. 6. Subjects who have participated in other clinical studies within the last one month prior to the current study or are planned to participate in other studies after obtaining informed consent for the current study. 7. Subjects who intend to become pregnant or lactating. 8. Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire. 9. Subjects who are judged as unsuitable for this study by physician.

Design outcomes

Primary

MeasureTime frame
Hematologic test, Blood biochemistry test, Urine test, Blood pressure/pulsation, Weight/body mass index, Interview, before and 2, 4 weeks after intake and Adverse events thorough the study.

Countries

Japan

Contacts

Public ContactNoriko Watanabe

TTC Co.,Ltd. Clinical Research Planning Department

n.watanabe@ttc-tokyo.co.jp03-5459-5329

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026